Bright Green
BGXX

$0.23

1.01%

Market Cap: 44.1M

About: Bright Green Corp is a provider of cannabis, cannabis-related products, and other legal medicinal plant-based therapies, manufactured for research and pharmaceutical applications, as well as being an active ingredient in consumer-based solutions. The company plans to focus on the development of cannabis strains and sales of products with high contents of CBN (cannabinol) and CBG (cannabigerol).

Employees: 5

Healthcare Medicinal Chemicals & Botanical Products

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

2.02% less ownership

Funds ownership: 7.82% [Q4 2023] → 5.8% (-2.02%) [Q1 2024]

2% less funds holding

Funds holding: 45 [Q4 2023] → 44 (-1) [Q1 2024]

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

19% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 16

45% less capital invested

Capital invested by funds: $4.75M [Q4 2023] → $2.6M (-$2.15M) [Q1 2024]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for BGXX.

See Analyst Rankings

Financial journalist opinion

GRANTS, NEW MEXICO, May 30, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (Nasdaq: BGXX) Dear BGXX Shareholders, I'm writing to you today to share an update on several developments for Bright Green Corporation (“Bright Green” or the “Company”) over the past few months. We've experienced massive shifts within the industry since the start of 2024 — shifts that have presented exciting growth opportunities for Bright Green.

CEO UPDATE

BRIGHT GREEN ANNOUNCES ITS EXPANSION CONTINUATION WITH A $100 MILLION SOLAR POWERED GENERATION FIELD TO SUPPLY HEAT AND ELECTRICITY TO ITS DRUG PRODUCTION AND MANUFACTURING FACILITY.

GRANTS, NEW MEXICO, March 14, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the “Company”) Today announced that BGXX will install a 102-megawatt solar field to power the electricity and heating requirements for the new $250 million Dalsem expansion project and commits to switch the existing facility that currently burns natural gas and heavy oil to solar. This ensures that the BGXX production and drug manufacturing requirements in Grants, New Mexico are carbon neutral.

BRIGHT GREEN ANNOUNCES ITS EXPANSION CONTINUATION WITH A $100 MILLION SOLAR POWERED GENERATION FIELD TO SUPPLY HEAT AND ELECTRICITY TO ITS DRUG PRODUCTION AND MANUFACTURING FACILITY.

BRIGHT GREEN ANNOUNCES PLANS FOR $250 MILLION EXPANSION OF ITS CONTROLLED SUBSTANCES DRUG PRODUCTION FACILITY IN GRANTS, NEW MEXICO AND OBTAINS $60 MILLION IN FINANCING

GRANTS, NEW MEXICO, March 12, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the “Company”) today announced that it has signed an agreement with Dalsem Greenhouse Technologies BV for a $250 million construction project to expand the Company's current research, production and extraction processing facility located in rural Grants, New Mexico (the “Dalsem Agreement”). The proposed expansion will add 7 million square feet of manufacturing and production capabilities. The Dalsem Agreement provides that Dalsem will construct the additional facility to its specifications and build them in a modular fashion.

BRIGHT GREEN ANNOUNCES PLANS FOR $250 MILLION EXPANSION OF ITS CONTROLLED SUBSTANCES DRUG PRODUCTION FACILITY IN GRANTS, NEW MEXICO AND OBTAINS $60 MILLION IN FINANCING

Bright Green Corporation (BGXX) submits for historic DEA Registration for Production of Schedule I and Schedule II controlled substances.

The application follows the Company's approval from the New Mexico Board of Pharmacy this year. GRANTS, NM, March 07, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation, a Delaware corporation (the “Company”), announced today the submission of its DEA Registration for Bulk Production of Schedule I and Schedule II Controlled Substances.

Bright Green Corporation (BGXX) submits for historic DEA Registration for Production of Schedule I and Schedule II controlled substances.

BRIGHT GREEN CORPORATION GAINS MOMENTUM FOR THEIR “DRUGS MADE IN AMERICA” PLATFORM WITH APPROVAL FOR THE RESEARCH, PRODUCTION AND MANUFACTURING OF ALL SCHEDULE I AND SCHEDULE II PLANT-BASED DRUGS

BRIGHT GREEN CORPORATION BREAKS NEW GROUND IN DOMESTIC PHARMACEUTICAL PRODUCTION GRANTS, N.M., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the “Company”) company announced today that final approval has been received from the New Mexico Board of Pharmacy and the DEA for unique licensing that allows Bright Green to register, license, and authorize Schedule I and Schedule II plant-based drugs and Active Pharmaceutical Ingredients (APIs) for research, production, and manufacturing purposes.

BRIGHT GREEN CORPORATION GAINS MOMENTUM FOR THEIR “DRUGS MADE IN AMERICA” PLATFORM WITH APPROVAL FOR THE RESEARCH, PRODUCTION AND MANUFACTURING OF ALL SCHEDULE I AND SCHEDULE II PLANT-BASED DRUGS

BRIGHT GREEN CORPORATION ANNOUNCES CHANGES TO BOARD OF DIRECTORS

CEO, Groovy Singh appointed as a new member of the Company's Board Founder, Lynn Stockwell, appointed as Chair of the Board of Directors Grants, New Mexico, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ: BGXX) – Bright Green Corporation, a Delaware corporation (the “Company”), announced Friday that CEO Groovy Singh is the newest member of the company's Board of Directors (the “Board”). Current board member and Co-Founder Lynn Stockwell was also announced as the new Chair of the Board.

BRIGHT GREEN CORPORATION ANNOUNCES CHANGES TO BOARD OF DIRECTORS

Bright Green Corporation announces the agreement to acquire platform technologies and associated intellectual property from C2 Wellness Corp.

Grants, New Mexico, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ: BGXX) today announced the agreement to purchase assets from C2 Wellness Corporation. (“C2”), a Wyoming registered company with an address at 30 N Gould St, Ste R, Sheridan, WY, that owns certain platform technologies and associated intellectual property invented and developed by the scientific team of C2.

Bright Green Corporation announces the agreement to acquire platform technologies and associated intellectual property from C2 Wellness Corp.

(Updated) U.S. Legal Cannabis Pioneer Bright Green Corporation Appoints Industry Veteran Groovy Singh as New Chief Executive Officer

Singh's appointment comes in support of the Company's next evolution, which will be focused on investing in top talent, commencement of commercial operations, and investing in clinical research and development of plant based therapies, and expanding into cultivation and manufacturing of other scheduled substances.

(Updated) U.S. Legal Cannabis Pioneer Bright Green Corporation Appoints Industry Veteran Groovy Singh as New Chief Executive Officer

Bright Green Announces Third Quarter 2023 Financial Update and Milestone Progress

Bright Green has achieved several key milestones throughout the Quarter advancing progress against its strategic plan.

Bright Green Announces Third Quarter 2023 Financial Update and Milestone Progress

Bright Green Corporation announces exclusive partnership with Asia Capital Pioneers Group to present new EB-5 offering

GRANT, N.M., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Bright Green Corporation (BGXX) (“BGXX”, “Bright Green” or the “Company”) today announced the Company's new alliance with Asia Capital Pioneers Group Inc. (“ACPG”), an Asia-based investment firm with global investments within high growth industries. ACPG will be BGXX's exclusive Asia partner, connecting the Company with investors that fulfill the requirements for permanent U.S. residency via an EB-5 Investment Visa in the Asia-Pacific region.

Bright Green Corporation announces exclusive partnership with Asia Capital Pioneers Group to present new EB-5 offering

See News Rankings